CCCC CCCC
Company Profile ↓Company Overview
CCCC (CCCC) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $35.95M (+1.0% YoY); net profit $-104.99M.
- Trailing 12 Months Year-on-year growth — revenue +1.0%.
- 5-Year Trend Long-term compounding — revenue CAGR -5.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -5.87% |
| 1 Year: | 1.02% |
Stock Price Performance
| 1 Year: | +72.38% |
| 6 Months: | +80.10% |
| 3 Months: | +21.89% |
| 1 Month: | -16.78% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)46.38 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -5.9% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 9.78M | 8.50M | 7.65M | 13.83M | 6.75M | 3.76M | 2.66M | 11.07M | 3.04M | 12.01M | 15.36M | 7.24M | 6.46M | 11.23M | 6.15M |
| Operating Income | -10.00M | -12.34M | -10.86M | -18.35M | -20.51M | -22.12M | -24.25M | -31.37M | -27.38M | -32.49M | -36.23M | -37.57M | -27.81M | -32.22M | -21.44M | -28.24M | -29.16M | -28.50M | -34.41M | -27.79M |
| Net Income | -10.09M | -11.91M | -10.79M | -21.84M | -20.97M | -22.58M | -24.68M | -31.62M | -27.41M | -31.96M | -34.78M | -35.92M | -27.04M | -28.36M | -17.72M | -24.67M | -26.32M | -26.02M | -32.17M | -25.13M |
| Diluted EPS | - | - | - | - | - | -0.51 | -0.51 | -0.65 | -0.56 | -0.65 | -0.71 | -0.73 | -0.55 | -0.41 | -0.26 | -0.35 | -0.37 | -0.37 | -0.44 | -0.20 |
| R&D Expense | 12.95M | 16.31M | 17.76M | 23.93M | 20.53M | 23.29M | 24.30M | 26.20M | 31.32M | 29.66M | 29.04M | 29.93M | 28.35M | 22.53M | 23.75M | 31.84M | 27.07M | 26.20M | 25.99M | 24.61M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | 45.78M | 31.10M | 20.76M | 35.58M | 35.95M |
| Operating Income | -35.45M | -60.45M | -82.13M | -129.53M | -139.03M | -119.61M | -115.22M |
| Net Income | -34.10M | -66.33M | -83.89M | -128.18M | -132.49M | -105.32M | -104.99M |
| Diluted EPS | - | - | -1.82 | -2.62 | -2.67 | -1.52 | -1.27 |
| R&D Expense | 48.06M | 78.44M | 94.67M | 117.84M | 117.71M | 110.64M | 104.24M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 118.26M | 400.14M | 506.76M | 430.84M | 376.45M | 349.60M | 359.07M |
| Total Equity | -79.75M | -111.96M | 280.79M | 389.61M | 289.23M | 246.11M | 215.99M | 256.59M |
| Cash & Equivalents | - | 90.55M | 181.73M | 76.12M | 29.75M | 126.59M | 55.50M | 74.60M |
| Long Term Debt | - | - | 10.05M | 10.77M | 9.20M | 0 | - | - |
| Total Liabilities | - | 119.23M | 119.35M | 117.16M | 141.61M | 130.34M | 133.62M | 102.49M |
| Current Liabilities | - | 33.64M | 43.85M | 51.25M | 44.55M | 42.77M | 45.18M | 33.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 55.61M | -67.25M | -86.97M | -105.94M | -106.84M | -65.16M | -98.69M |
| Investing Cash Flow | -1.62M | -190.50M | -189.34M | 58.42M | 158.35M | -51.27M | -8.60M |
| Financing Cash Flow | 244.00K | 348.93M | 171.40M | 1.15M | 45.49M | 45.34M | 126.40M |
| Capital Expenditure | -1.35M | -650.00K | -1.28M | -5.50M | -1.71M | -180.00K | -607.00K |
| Free Cash Flow | 54.27M | -67.90M | -88.24M | -111.44M | -108.55M | -65.34M | -99.30M |
| Share Buybacks | 30.00K | 194.00K | - | 0 | 110.00K | 194.00K | 193.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | -179.4% | -416.6% | -669.8% | -336.1% | -320.5% |
| Net Margin % | - | - | -183.2% | -412.2% | -638.3% | -296.0% | -292.1% |
| ROE % | 30.5% | -23.6% | -21.5% | -44.3% | -53.8% | -48.8% | -40.9% |
| ROCE % | -41.9% | -17.0% | -18.0% | -33.5% | -41.7% | -39.3% | -35.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CCCC
C4 Therapeutics Stock Price Forecast. Should You Buy CCCC? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTFB6VHIzQkJkUXZrTlNpaGstNEdLR3BBbnVSeWVqM195QXpSZk1zUklWOVpfTDhrU3B6dDdCUmZOXzFNbkJmXy1kdg?oc=5" target="_blank">C4 Therapeutics Stock Price Forecast. Should You Buy CCCC?</a> &…
Analysts See Significant Upside in C4 Therapeutics (CCCC) Stock - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPQlNGSVZGUU5QU09GWjBhYnBFMktPN0t1RHk4dkdhV3pWOW9KaHE2OFk5Q014YXE4M0xyWWI0bkJXUkN6ZThmVDh3dVFQYU9HMmZ3S0FFcks0RUY4SXhOYVk1YUF1aWFveW9fRW5nRjAtVzU1cFZlM1dNMFVtRHVLLW9fMFUzTzFYNFpHaW…
$CCCC stock is down 8% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOU1VIR3czYklrZDNIVUR0VXR0Y09KMjBXQmJ6SUFqaDhVTW11SDdNREg3RURMUm9JSlh6cy1nYzJud2VIREYwdTdHWDdTbWd0YWFnLTVpTlVtNUx2QmxhQlQ4cmFha0FyWTVXUFk3NjhvNmw1VXdic0FUcWhoSkJvaEI5WlduYS0xM1FfR2…
CCCC Stock Reverses Pre-Market Gains After Roche Tie-Up To Develop Cancer Treatments - Retail Sees Strong Upside - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi2AFBVV95cUxNNFhwZFByVEFDdFFBdXhiZXFsZ0FhbWFRbE5HdENvMm12d1FIZzI0MDlYdzRwVjFwTEY2ajNhZ2pwT0ZyTjR1cFEtNzQ3bERzLTdMZHpoQWM3NTUwbUUySHBtSjRGaEczWkE0WDVQVTNRV19ZeUI1RFQyU1h0NFBxQXdYbmlqSDF1ZmJ0a0…
Director Steven Hoerter gets 62,000 C4 Therapeutics (CCCC) options at $4.25 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiswFBVV95cUxNWHpaNmp2dFZmYXgyaXdVS1VMdlp5TE9JeFNreWpVUGlRYm1ZRS0zdXdOZE5KSVhqaE1Pa3REcW11RFBMVEtsa0RkQTRDZlhhekdUUEZlc0VVMEpIT25fV29BSlpyY1dCaktKMUowaVA4eXRCSjlyRXJtUXFTUU5icGV5Z2JIa2pmNTZOaz…
C4 Therapeutics, Inc. Revenue Breakdown – NASDAQ:CCCC - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE8zVXlOM285ZnNtX1ZCMFdsaWVSaVR0OEpMd0VIVTVxYlVuVlJ5ZHhiWk5UV25lWG02M0ZsZTluSHdzS1RqTzhGUjZCYVBRV3o3X3p2UHMwS3V1cy1hVWtsZ1VjeEl0OGJCdThGYy1kUHhLNTZhalhJ?oc=5" target="_blank">C4 Ther…
CCCC — Frequently Asked Questions
What is the current share price of CCCC?
As of 2026-08-05 17:25 PDT, CCCC trades at $3.62 on NASDAQ/NYSE. Its 52-week range is $1.71 to $4.67.
What is the P/E ratio of CCCC?
CCCC trades at a trailing price-to-earnings (P/E) ratio of -2.85.
What is the return on equity (ROE) of CCCC?
CCCC has a return on equity (ROE) of -40.92%. Its return on capital employed (ROCE) is -35.34%.
Is CCCC a good stock to buy?
This page provides a data-driven analysis of CCCC, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.